Publicação:
How can micelle systems be rebuilt by a heating process?

dc.contributor.authorda Silva-Filho, Miguel Adelino
dc.contributor.authorVieira da Silva Siqueira, Scheyla Daniela
dc.contributor.authorFreire, Larissa Bandeira
dc.contributor.authorde Araujo, Ivonete Batista
dc.contributor.authorGyselle de Holanda e Silva, Kattya
dc.contributor.authorMedeiros, Aldo da Cunha
dc.contributor.authorAraujo-Filho, Irami
dc.contributor.authorOliveira, Anselmo Gomes de [UNESP]
dc.contributor.authorTabosa do Egito, Eryvaldo Socrates
dc.contributor.institutionUniversidade Federal do Rio Grande do Norte (UFRN)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T13:25:02Z
dc.date.available2014-05-20T13:25:02Z
dc.date.issued2012-01-01
dc.description.abstractThe aim of this work was to evaluate how an aqueous micellar system - containing Amphotericin B (AmB) and sodium deoxycholate (DOC) can be rebuilt after heating treatment. Also, a review of the literature on the physicochemical and biological properties of this new system was conducted. Heated (AmB-DOC-H) and unheated (AmB-DOC) micelles were then diluted at four different concentrations (50 mg.L-1, 5 mg.L-1, 0.5 mg.L-1, and 0.05 mg.L-1) to perform physicochemical studies and a pharmacotoxicity assay, in which two cell models were used for the in vitro experiments: red blood cells (RBC) from human donors and Candida parapsilosis (Cp). While potassium (K+) and hemoglobin leakage from RBC were the parameters used to evaluate acute and chronic toxicity, respectively, the efficacy of AmB-DOC and AmB-DOC-H were assessed by K+ leakage and cell survival rate from Cp. The spectral study revealed a slight change in the AmB-DOC aggregate peak from 327 nm to 323 nm, which is the peak for AmB-DOC-H. Although AmB-DOC and AmB-DOC-H exhibited different behavior for hemoglobin leakage, AmB-DOC produced higher leakage than AmB-DOC-H at high concentrations (from 5 mg.L-1). For K+ leakage, both AmB-DOC and AmB-DOC-H showed a similar profile for both cell models, RBC and Cp (P < 0.05). AmB-DOC-H and AmB-DOC also revealed a similar profile of activity against Cp with an equivalent survival rate. In short, AmB-DOC-H showed much less toxicity than AmB-DOC, but remained as active as AmB-DOC against fungal cells. The results highlight the importance of this new procedure as a simple, inexpensive, and safe way to produce a new kind of micelle system for the treatment of systemic fungal infections.en
dc.description.affiliationFed Univ Rio Grande Norte UFRN, Dispersed Syst Lab, BR-59094450 Natal, RN, Brazil
dc.description.affiliationUniv Fed Rio Grande do Norte, Dept Pharm, Natal, RN, Brazil
dc.description.affiliationUniv Fed Rio Grande do Norte, Dept Expt Surg, Natal, RN, Brazil
dc.description.affiliationColl Pharmaceut Sci UNESP, Dept Drugs & Med, São Paulo, Brazil
dc.description.affiliationUnespColl Pharmaceut Sci UNESP, Dept Drugs & Med, São Paulo, Brazil
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdCNPq: 301979/04-9
dc.description.sponsorshipIdCNPq: 473882/04-3
dc.description.sponsorshipIdCNPq: 47836/01-7-NV
dc.format.extent141-150
dc.identifierhttp://dx.doi.org/10.2147/IJN.S25761
dc.identifier.citationInternational Journal of Nanomedicine. Albany: Dove Medical Press Ltd, v. 7, p. 141-150, 2012.
dc.identifier.doi10.2147/IJN.S25761
dc.identifier.fileWOS000302700700001.pdf
dc.identifier.issn1178-2013
dc.identifier.lattes9114495952533044
dc.identifier.urihttp://hdl.handle.net/11449/7920
dc.identifier.wosWOS:000302700700001
dc.language.isoeng
dc.publisherDove Medical Press Ltd
dc.relation.ispartofInternational Journal of Nanomedicine
dc.relation.ispartofjcr4.370
dc.relation.ispartofsjr1,225
dc.rights.accessRightsAcesso abertopt
dc.sourceWeb of Science
dc.subjectmicellesen
dc.subjectnanotechnologyen
dc.subjectpre-heated amphotericin Ben
dc.subjectsuper-aggregatesen
dc.titleHow can micelle systems be rebuilt by a heating process?en
dc.typeArtigopt
dcterms.licensehttp://www.dovepress.com/why_publish_with_dove.php?content_id=3045
dcterms.rightsHolderDove Medical Press Ltd
dspace.entity.typePublication
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscoverye214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.author.lattes9114495952533044[8]
unesp.author.orcid0000-0002-2180-3991[9]
unesp.author.orcid0000-0002-0107-9940[8]
unesp.author.orcid0000-0002-9997-4870[1]
unesp.author.orcid0000-0003-2471-7447[7]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
WOS000302700700001.pdf
Tamanho:
480.14 KB
Formato:
Adobe Portable Document Format

Licença do Pacote

Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: